José Luis López-Sendón

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2812416/publications.pdf

Version: 2024-02-01

96 papers

15,011 citations

29 h-index 94 g-index

99 all docs 99 docs citations 99 times ranked 16025 citing authors

#	Article	IF	CITATIONS
1	Tbx5 variants disrupt Nav1.5 function differently in patients diagnosed with Brugada or Long QT Syndrome. Cardiovascular Research, 2022, 118, 1046-1060.	1.8	15
2	Inhibition of p38 MAP kinase in patients with ST-elevation myocardial infarction – findings from the LATITUDE–TIMI 60 trial. American Heart Journal, 2022, 243, 147-157.	1.2	5
3	Cardiovascular risk factors during cancer treatment. Prevalence and prognostic relevance: insights from the CARDIOTOX registry. European Journal of Preventive Cardiology, 2022, 29, 859-868.	0.8	25
4	Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study. European Journal of Preventive Cardiology, 2022, 28, 1864-1872.	0.8	19
5	Ranolazine: a better understanding of its pathophysiology and patient profile to guide treatment of chronic stable angina. Future Cardiology, 2022, 18, 235-251.	0.5	8
6	Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non–Critically III Hospitalized Patients With COVID-19. JAMA - Journal of the American Medical Association, 2022, 327, 227.	3.8	89
7	Blood Pressure Drops During Hospitalization for Acute Heart Failure Treated With Serelaxin: A Patient-Level Analysis of 4 Randomized Controlled Trials. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121009199.	1.6	3
8	Predictors of Left Main Coronary Artery Disease in the ISCHEMIA Trial. Journal of the American College of Cardiology, 2022, 79, 651-661.	1.2	14
9	Treatment adherence and effect of concurrent statin intensity on the efficacy and safety of alirocumab in a real-life setting: results from ODYSSEY APPRISE. Archives of Medical Science, 2022, 18, 285-292.	0.4	13
10	Age and Gender influence on time of arrival for STEMI patients during Covid-19 pandemic. American Journal of Emergency Medicine, 2021, 42, 244-245.	0.7	14
11	CT Angiography Followed by Invasive Angiography in Patients With Moderate or Severe Ischemia-Insights From the ISCHEMIA Trial. JACC: Cardiovascular Imaging, 2021, 14, 1384-1393.	2.3	37
12	Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Longâ€Term Ticagrelor in Stable Patients With Prior Myocardial Infarction. Journal of the American Heart Association, 2021, 10, e017008.	1.6	17
13	Pharmacogenomics of the Efficacy and Safety of Colchicine in COLCOT. Circulation Genomic and Precision Medicine, 2021, 14, e003183.	1.6	7
14	Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]). American Journal of Cardiology, 2021, 148, 146-150.	0.7	15
15	Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy. Stroke, 2021, 52, 2096-2105.	1.0	25
16	Natural History of Patients With Ischemia and No Obstructive Coronary Artery Disease. Circulation, 2021, 144, 1008-1023.	1.6	56
17	Comparison of Days Alive Out of Hospital With Initial Invasive vs Conservative Management. JAMA Cardiology, 2021, 6, 1023.	3.0	10
18	ISCHEMIA Trial: Key Questions and Answers. European Cardiology Review, 2021, 16, e34.	0.7	2

#	Article	lF	Citations
19	Systolic Blood Pressure and Outcome in Patients Admitted With Acute Heart Failure: An Analysis of Individual Patient Data From 4 Randomized Clinical Trials. Journal of the American Heart Association, 2021, 10, e022288.	1.6	8
20	State of the art approach to managing angina and ischemia: tailoring treatment to the evidence. European Journal of Internal Medicine, 2021, 92, 40-47.	1.0	4
21	Gender differences in antithrombotic treatment in patients with atrial fibrillation from Spain versus the rest of Western Europe. GLORIA-AF Program. Medicina ClÃnica, 2021, , .	0.3	1
22	Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention. PharmacoEconomics - Open, 2020, 4, 485-497.	0.9	6
23	Long term clinical outcomes in survivors after out-of-hospital cardiac arrest. European Journal of Internal Medicine, 2020, 74, 49-54.	1.0	18
24	Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease in Patients With a History of Heart Failure or Left Ventricular Dysfunction. Circulation, 2020, 142, 1725-1735.	1.6	77
25	Arterial thrombotic complications in hospitalized patients with COVID-19. Revista Espanola De Cardiologia (English Ed), 2020, 73, 769-771.	0.4	28
26	Initial Invasive or Conservative Strategy for Stable Coronary Disease. New England Journal of Medicine, 2020, 382, 1395-1407.	13.9	1,508
27	Association of Sex With Severity of Coronary Artery Disease, Ischemia, and Symptom Burden in Patients With Moderate or Severe Ischemia. JAMA Cardiology, 2020, 5, 773.	3.0	101
28	COVID-19 and simultaneous thrombosis of two coronary arteries. Revista Espanola De Cardiologia (English Ed), 2020, 73, 676-677.	0.4	16
29	Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. European Heart Journal, 2020, 41, 1720-1729.	1.0	154
30	Comparison of Noninvasive Cardiac Test Strategies for Newly Diagnosed Chagas Disease in a Non-Endemic Zone. American Journal of Tropical Medicine and Hygiene, 2020, 103, 1480-1486.	0.6	1
31	Device to Narrow the Coronary Sinus in Refractory Angina. Revista Espanola De Cardiologia (English) Tj ETQq1 1	0.784314 0.4	rgBT /Overlo
32	Precision and reproducibility of non-automatic measurement of the QRS complex in potential candidates for cardiac resynchronization therapy. Journal of Electrocardiology, 2019, 57, 90-94.	0.4	2
33	Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 200-206.	1.4	25
34	72-Year-old woman with effort angina >3 <12 months after acute myocardial infarction. European Heart Journal Supplements, 2019, 21, C21-C23.	0.0	1
35	Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. New England Journal of Medicine, 2019, 380, 1326-1335.	13.9	687
36	Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial. JAMA Cardiology, 2019, 4, 273.	3.0	100

#	Article	IF	Citations
37	Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight. Circulation, 2019, 139, 2292-2300.	1.6	78
38	Baseline Predictors of Low-Density Lipoprotein Cholesterol and Systolic Blood Pressure Goal Attainment After 1 Year in the ISCHEMIA Trial. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e006002.	0.9	26
39	Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. New England Journal of Medicine, 2019, 381, 2497-2505.	13.9	1,696
40	Impact of stable angina on health status and quality of life perception of currently treated patients. The BRIDGE 2 survey. European Journal of Internal Medicine, 2019, 70, 60-67.	1.0	14
41	Anti-anginal drugs–beliefs and evidence: systematic review covering 50 years of medical treatment. European Heart Journal, 2019, 40, 190-194.	1.0	49
42	StaBle Angina: PeRceptlon of NeeDs, Quality of Life and ManaGemEnt of Patients (BRIDGE Study)—A Multinational European Physician Survey. Angiology, 2019, 70, 397-406.	0.8	9
43	Efficacy and safety of serelaxin when added to standard of care in patients with acute heart failure: results from a PROBE study, RELAXâ€AHFâ€EU. European Journal of Heart Failure, 2019, 21, 322-333.	2.9	24
44	Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients WithÂMultivessel Coronary Disease. Journal of the American College of Cardiology, 2018, 71, 489-496.	1.2	56
45	Dataset regarding baseline and follow-up characteristics of out-of-hospital cardiac arrest patients focused on neurological outcomes. Data in Brief, 2018, 21, 1140-1144.	0.5	2
46	Long-term neurological outcomes in out-of-hospital cardiac arrest patients treated with targeted-temperature management. Resuscitation, 2018, 133, 33-39.	1.3	33
47	Edoxaban Versus Warfarin in LatinÂAmerican Patients With AtrialÂFibrillation. Journal of the American College of Cardiology, 2018, 72, 1466-1475.	1.2	10
48	Previous and New Onset Atrial Fibrillation and Associated Outcomes in Acute Coronary Syndromes (from the Global Registry of Acute Coronary Events). American Journal of Cardiology, 2018, 122, 944-951.	0.7	11
49	Prevalence of Neuroendocrine Tumors in Patients With Cyanotic Congenital Heart Disease. Revista Espanola De Cardiologia (English Ed), 2017, 70, 673-675.	0.4	4
50	Pharmacological reasons that may explain why randomized clinical trials have failed in acute heart failure syndromes. International Journal of Cardiology, 2017, 233, 1-11.	0.8	8
51	Diagnostic Value of NT-proBNP for Early Identification of Chagas Cardiomyopathy in Non-endemic Areas. Revista Espanola De Cardiologia (English Ed), 2017, 70, 783-785.	0.4	1
52	Growth Differentiation Factor 15 at 1ÂMonth After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding. Journal of the American Heart Association, 2017, 6, .	1.6	27
53	Use of troponin assay 99th percentile as the decision level for myocardial infarction diagnosis. American Heart Journal, 2017, 190, 135-139.	1.2	26
54	New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment. European Journal of Heart Failure, 2017, 19, 718-727.	2.9	17

#	Article	IF	CITATIONS
55	ST-elevation Myocardial Infarction in Anomalous Origin of Right Coronary Artery From the Left Sinus of Valsalva and Interarterial Course. Revista Espanola De Cardiologia (English Ed), 2017, 70, 596-598.	0.4	1
56	Selfâ€Reported Health and Outcomes in Patients With Stable Coronary Heart Disease. Journal of the American Heart Association, 2017, 6, .	1.6	8
57	Remarks on the Position Paper on Cardio-Onco-Hematology and Remarks on the Review of Cardiac Imaging Modalities for the Detection of Cardiotoxicity. Response. Revista Espanola De Cardiologia (English Ed), 2017, 70, 1029-1030.	0.4	0
58	Different patterns of in-stent coverage in drug-eluting stents. Revista Portuguesa De Cardiologia, 2017, 36, 873-874.	0.2	O
59	Concomitant Rivaroxaban and Dronedarone Administration in Patients With Nonvalvular Atrial Fibrillation. Revista Espanola De Cardiologia (English Ed), 2017, 70, 121-122.	0.4	4
60	Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial. European Heart Journal, 2017, 38, 2813-2822.	1.0	45
61	Una historia resumida. Impacto de los avances en cardiopatÃa isquémica. Revista Espanola De Cardiologia Suplementos, 2017, 17, 2-6.	0.2	1
62	Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. European Journal of Heart Failure, 2016, 18, 672-683.	2.9	21
63	Management of stable angina: A commentary on the European Society of Cardiology guidelines. European Journal of Preventive Cardiology, 2016, 23, 1401-1412.	0.8	30
64	Temporal trends in all-cause mortality according to smoking status: Insights from the Global Registry of Acute Coronary Events. International Journal of Cardiology, 2016, 218, 291-297.	0.8	8
65	Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. Journal of the American College of Cardiology, 2016, 67, 2719-2728.	1.2	303
66	Influence of the temperature on the moment of awakening in patients treated with therapeutic hypothermia after cardiac arrest. Resuscitation, 2016, 103, 32-36.	1.3	31
67	Challenges in Oral Lipid-lowering Therapy: Position Document of the Spanish Society of Cardiology. Revista Espanola De Cardiologia (English Ed), 2016, 69, 1083-1087.	0.4	4
68	Bioabsorbable Intracoronary Matrix for Prevention of Ventricular Remodeling After Myocardial Infarction. Journal of the American College of Cardiology, 2016, 68, 715-723.	1.2	79
69	Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. New England Journal of Medicine, 2016, 375, 1131-1141.	13.9	692
70	Medical treatment of stable angina: A tailored therapeutic approach. International Journal of Cardiology, 2016, 220, 445-453.	0.8	36
71	Reduction in Total Cardiovascular Events WithÂEzetimibe/Simvastatin Post-Acute Coronary Syndrome. Journal of the American College of Cardiology, 2016, 67, 353-361.	1.2	173
72	Clinical Characteristics, Management, and Outcomes of Acute Coronary Syndrome in Patients With Right Bundle Branch Block on Presentation. American Journal of Cardiology, 2016, 117, 754-759.	0.7	15

#	Article	IF	CITATIONS
73	History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. American Heart Journal, 2016, 175, 175-183.	1.2	16
74	Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y $<$ sub $>$ 12 $<$ /sub $>$ inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. European Heart Journal, 2016, 37, 1133-1142.	1.0	138
75	Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial. Lancet, The, 2016, 387, 349-356.	6.3	109
76	Long-term Follow-up After Transcatheter Aortic Valve Implantation for Severe Aortic Stenosis. Revista Espanola De Cardiologia (English Ed), 2016, 69, 37-44.	0.4	8
77	Prognostic impact of decisions taken by the heart team in patients evaluated for transcatheter aortic valve implantation. Revista Portuguesa De Cardiologia, 2015, 34, 587-595.	0.2	1
78	Diagnosis and management of pulmonary embolism in critical situations: A cardiac challenge. Revista Portuguesa De Cardiologia, 2015, 34, 703-704.	0.2	0
79	Contemporary registries on P2Y12 inhibitors in patients with acute coronary syndromes in Europe: overview and methodological considerations: Table 1. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 232-244.	1.4	13
80	Earlobe Crease Shapes and Cardiovascular Events. American Journal of Cardiology, 2015, 116, 286-293.	0.7	34
81	Late Consequences of Acute Coronary Syndromes: Global Registry of Acute Coronary Events (GRACE) Follow-up. American Journal of Medicine, 2015, 128, 766-775.	0.6	81
82	Quality Markers in Cardiology. Main Markers to Measure Quality of Results (Outcomes) and Quality Measures Related to Better Results in Clinical Practice (Performance Metrics). INCARDIO (Indicadores) Tj ETQqO Revista Espanola De Cardiologia (English Ed.), 2015, 68, 976-995.e10.	0 O rgBT /0	Overlock 10 T
83	Unresolved issues in the management of chronic stable angina. International Journal of Cardiology, 2015, 201, 200-207.	0.8	27
84	Heart failure years after cancer treatment. Future Cardiology, 2015, 11, 433-440.	0.5	2
85	Poor Anticoagulation Control in Atrial Fibrillation: How Much Longer?. Revista Espanola De Cardiologia (English Ed), 2015, 68, 740-742.	0.4	6
86	High-grade atrioventricular block in acute coronary syndromes: insights from the Global Registry of Acute Coronary Events. European Heart Journal, 2015, 36, 976-983.	1.0	61
87	Clinical characteristics and outcomes of acute coronary syndrome patients with left anterior hemiblock. Heart, 2014, 100, 1456-1461.	1.2	3
88	Beta-blocker Use in ST-segment Elevation Myocardial Infarction in the Reperfusion Era (GRACE). American Journal of Medicine, 2014, 127, 503-511.	0.6	28
89	Interpretation of optical coherence tomography images. Lancet, The, 2014, 383, 1887-1888.	6.3	0
90	Cardiac Arrest Survivors Before They Reach Hospital. Beyond Cardiopulmonary Resuscitation. Revista Espanola De Cardiologia (English Ed), 2013, 66, 606-608.	0.4	1

#	Article	IF	CITATIONS
91	New Oral Anticoagulants in Nonvalvular Atrial Fibrillation: Findings and Implications of the ROCKET Study. Response. Revista Espanola De Cardiologia (English Ed), 2013, 66, 758-759.	0.4	O
92	Percutaneous Balloon Pericardiotomy as the Initial and Definitive Treatment for Malignant Pericardial Effusion. Revista Espanola De Cardiologia (English Ed), 2013, 66, 357-363.	0.4	8
93	Apixaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine, 2011, 365, 981-992.	13.9	7,537
94	Factors related to heart rupture in acute coronary syndromes in the Global Registry of Acute Coronary Events. European Heart Journal, 2010, 31, 1449-1456.	1.0	185
95	In-Hospital Outcomes Associated With Fibrinolytic and Thienopyridine Use in Patients With ST-Segment Elevation Acute Myocardial Infarction. The Global Registry of Acute Coronary Events. Revista Espanola De Cardiologia (English Ed), 2009, 62, 501-509.	0.4	1
96	Recommendations on sub-speciality accreditation in cardiology: The Coordination Task Force on Sub-speciality Accreditation of the European Board for the Speciality of Cardiology. European Heart Journal, 2007, 28, 2163-2171.	1.0	26